相关临床试验
134
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1640
进行中（未招募）
7
5.2%
已完成
77
57.5%
Enrolling By Invitation
1
0.8%
尚未招募
5
3.7%
招募中
15
11.2%
终止
4
3.0%
Unknown
25
18.7%
暂无批准数据
- A 10-year randomized controlled trial found that arthroscopic partial meniscectomy for degenerative meniscus tears provided no benefit over sham surgery and resulted in worse knee function scores. - The FIDELITY study tracked 146 patients and found that 81% of surgery patients developed osteoarthritis progression compared to 70% in the placebo group, with more requiring subsequent knee procedures. - Despite evidence against the procedure, some orthopedic organizations continue to endorse the surgery, illustrating the challenge of abandoning ineffective therapies in medicine. - Clinical practice has shifted toward conservative management, with surgery rates dropping from three-quarters to approximately one-quarter of patients as guidelines now recommend extended waiting periods and physiotherapy first.
- Avenue Biosciences secured $5.7 million in seed extension funding to advance its high-throughput protein engineering platform that addresses manufacturing bottlenecks in biologics development. - The company's technology screens thousands of signal peptide variants in parallel to optimize protein secretion, potentially cutting years from development timelines and reducing manufacturing costs. - The platform targets complex therapeutic proteins including multispecific antibodies, AI-designed proteins, and gene therapies across oncology, rare diseases, and immunology applications. - Avenue has already generated revenue in its first year with established CDMOs and pharmaceutical companies as customers, demonstrating early commercial validation of its approach.
- A randomized placebo-controlled Finnish study found that aspirin therapy after desensitization does not provide significant relief for patients with chronic rhinosinusitis with nasal polyps who are hypersensitive to NSAIDs. - Only 25% of patients receiving aspirin could be classified as benefiting from therapy, while 18% had to discontinue treatment due to adverse effects including respiratory symptoms and bleeding tendency. - The findings challenge the current practice of long-term aspirin therapy for N-ERD patients and suggest clinicians should consider more effective biologic treatments despite their higher cost.
- A Finnish study demonstrates that drug sensitivity testing can identify acute myeloid leukemia (AML) patients likely to benefit from venetoclax and azacitidine, improving treatment outcomes. - The study showed that leukemia cells' sensitivity to venetoclax in lab tests correlated with improved patient response and longer survival rates in AML patients. - This personalized approach, involving 104 AML patients, has accelerated access to venetoclax in Finland, reducing adverse effects and the costs of ineffective treatments. - The rapid turnaround of sensitivity data, within three days, enabled more personalized treatment decisions, with potential for testing other drugs in the future.
